TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8698737
Drug: Dexverapamil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexverapamil plus chemotherapy (vindesine/etoposide)
Study: 8698737
Drug: Chemotherapy (vindesine/etoposide)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vindesine/etoposide) alone
Study: 302111
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vasopressin via peripheral vein
Study: 302111
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of vasopressin via superior mesenteric artery (SMA)
Study: 29627898
Drug: SSRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI treatment with paroxetine for 8 weeks
Study: 9491842
Drug: Vancomycin therapy
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin therapy
Study: 8726538
Drug: Intranasal apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal apomorphine monotherapy
Study: 9756146
Drug: Intranasal apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal apomorphine
Study: 8726538
Drug: Intranasal apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal apomorphine with trimethobenzamide
Study: 1756271
Drug: melphalan (L-PAM)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan (L-PAM)
Study: 1756271
Drug: post-operative radiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: post-operative radiation therapy (RT)
Study: 7169959
Drug: Oestradiol diether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol diether (promestriene) administered via gynaecological capsules for 40 consecutive days
Study: 7169959
Drug: Excipient (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient (control) administered via gynaecological capsules for 40 consecutive days
Study: 11180035
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus (5 mg)
Study: 17122448
Drug: Dual ET-receptor
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ET-receptor blockade in controls
Study: 17122448
Drug: Dual ET-receptor
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual ET-receptor blockade in SCI
Study: 17122448
Drug: Selective ET(A)-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective ET(A)-receptor blockade in SCI
Study: 8555852
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) - 16 individual weekly sessions in addition to medical care
Study: 1810080
Drug: Pamidronate 75
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 75 mg daily
Study: 9797692
Drug: Pamidronate 150
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 150 mg daily
Study: 30528802
Drug: Weekly paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly paclitaxel, liposomal doxorubicin (plus carboplatin in TNBC) (PM(Cb))
Study: 28198120
Drug: Lecithinized curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithinized curcumin (1 g/day for 6 weeks)
Study: 28198120
Drug: Unformulated curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unformulated curcumin (1 g/day for 6 weeks)
Study: 23078651
Drug: Pimobendan (Vetmedin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (Vetmedin capsules)
Study: 19177449
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (10-15 ng/mL) plus intravenous MMF (1 g twice daily) with corticosteroids
Study: 19177449
Drug: Reduced-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tacrolimus (5-8 ng/mL) plus intravenous MMF (1 g twice daily) with corticosteroids
Study: 17150015
Drug: Gene and
Normalized name: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene and cell therapies for myocardial neovascularisation
Study: 10504080
Drug: Alcohol epithelial
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol epithelial removal (20% ethanol solution applied for 20 seconds)
Study: 8695463
Drug: Assessment and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment and treatment in primary care using a trained nurse
Study: 1654136
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (four consecutive, logarithmically increasing doses)
Study: 27920497
Drug: CKD‐828 2.5/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD‐828 2.5/40 mg
Study: 27920497
Drug: CKD‐828 2.5/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD‐828 2.5/80 mg
Study: 27920497
Drug: S‐amlodipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐amlodipine 2.5 mg
Study: 12669122
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous LMWH (bemiparin) for one week (group B)
Study: 12669122
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily bemiparin in a therapeutic dose for one week followed by a maintenance dose for 12 weeks (group C)
Study: 3972652
Drug: Benznidazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (up to 40 mg/kg)
Study: 3972652
Drug: CCNU (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (130 mg/m2)
Study: 30858208
Drug: Omadacycline 200
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 200 mg i.v. on day 1, then 300 mg orally q24h
Study: 30858208
Drug: Omadacycline 300
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 300 mg orally q12h on day 1, then 300 mg orally q24h
Study: 30858208
Drug: Omadacycline 450
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 450 mg orally q12h on day 1, then 450 mg orally q24h
Study: 22340605
Drug: Optical Path
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optical Path Difference Custom Aspheric Treatment (OPDCAT)
Study: 17572410
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for 6 months
Study: 15969897
Drug: Montelukast 4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4‐mg oral granules
Study: 8572359
Drug: Epidural catheters
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheters resulting in intravenous cannulation
Study: 8383088
Drug: No antitumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antitumor therapy (n = 36)
Study: 29489046
Drug: Prazosin (alpha-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (alpha-adrenergic agonist)
Study: 27439724
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion intervention (INT) delivered by trained Navajo lay health workers, including 5 interactions for children, 4 for parents, and 4 fluoride varnish applications over 3 years.
Study: 27439724
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion intervention (INT)
Study: 27439724
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion intervention (INT) among adherent children
Study: 21674393
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy using MIME (high-dose, 30 hours)
Study: 21674393
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy using MIME (low-dose, 15 hours)
Study: 21674393
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional therapy, up to 15 hours)
Study: 18680490
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 110 microg once daily
Study: 18680490
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 55 microg once daily
Study: 2554244
Drug: Oral rhesus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rhesus rotavirus vaccine (RRV) with oral poliovirus vaccine (OPV)
Study: 2554244
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral poliovirus vaccine (OPV)
Study: 2554244
Drug: Oral rhesus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rhesus rotavirus vaccine (RRV) 2 weeks after OPV
Study: 28878181
Drug: DHA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (200 mg/day) and ARA (200 mg/day) supplement
Study: 523503
Drug: Furosemide (oral)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (oral)
Study: 27530232
Drug: Furosemide (intravenous)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (intravenous)
Study: 24960147
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg qd
Study: 9035016
Drug: ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 600 mg qid
Study: 21544882
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza hydrophilic extract (SMHE) plus hypoglycemic therapy
Study: 21544882
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus hypoglycemic therapy
Study: 17601439
Drug: Misted administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misted administration of tropicamide 1.0% (6 microl)
Study: 17601439
Drug: Conventional drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drop administration of tropicamide 1.0% (30 microl)
Study: 15177812
Drug: Treatment-refractory patients
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-refractory patients with schizophrenia
Study: 12408210
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (for smokers ready to quit)
Study: 9583345
Drug: Brief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief treatment of depression (16-week duration)
Study: 9583345
Drug: Independent assessments
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent assessments during treatment
Study: 7661573
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron capsule
Study: 2589659
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (CYS) given 4 to 7 hours preoperatively
Study: 2589659
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (CYS) given less than 4 hours preoperatively
Study: 2589659
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (CYS) given greater than 7 hours preoperatively
Study: 7002354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Persantine and aspirin
Study: 19995094
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg
Study: 7014694
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream (15 patients)
Study: 7014694
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution (11 patients)
Study: 21445638
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg/day
Study: 1663914
Drug: Baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10 mg)
Study: 27184170
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg
Study: 26608067
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg orally twice daily)
Study: 23885048
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (5000 IU/d)
Study: 20950224
Drug: Certoparin 3000
Normalized name: certoparin
DrugBank: Certoparin (DB09261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin 3000 IU daily
Study: 20950224
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) 7500 IU twice daily
Study: 12370595
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation program (twice a week for 6 weeks)
Study: 2012462
Drug: High-dose ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketoconazole (800 mg/kg per day, orally)
Study: 2012462
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg per day, intravenously)
Study: 14511998
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (aspirin, 325 mg once daily or ticlopidine, 250 mg twice daily)
Study: 12947997
Drug: Nasal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal immunotherapy
Study: 10867377
Drug: Bronchial immunotherapy
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial immunotherapy
Study: 1335651
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of 0, 1 and 2 months with a booster at month 12
Study: 1335651
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (SmithKline Beecham Biological), vaccination schedule of day 0 and 14 with a booster at month 7
Study: 29785045
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation (FES) therapy (50 Hz/500 µs) for 4 weeks, with two weekly sessions lasting 15 minutes each, intensity lower than the motor threshold.
Study: 29785045
Drug: Placebo FES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo FES treatment following the same routine as the IG.
Study: 26946725
Drug: Ginger-partition moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger-partition moxibustion combined with glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Study: 26946725
Drug: Simple oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oral glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Study: 23712600
Drug: niacin/laropiprant (1000/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/laropiprant (1000/20 mg daily for 4 weeks and 2000/40 mg daily thereafter)
Study: 17913310
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage trivalent influenza vaccine (60 microg of HA for each component)
Study: 17913310
Drug: Licensed vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccine (15 microg of HA for each component)
Study: 11910662
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol + 5 mg dydrogesterone
Study: 11910662
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol + 10 mg dydrogesterone
Study: 2298969
Drug: Intralesional cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional cyclosporine administered three times weekly for 4 weeks
Study: 6110570
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (in vitro)
Study: 28223373
Drug: NICU-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: NICU-based interventions (including cognitive behavioral therapy)
Study: 28223373
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy interventions
Study: 23280223
Drug: Nifedipine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (80 mg/d for 12 days)
Study: 20147572
Drug: Diazepam 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 30 mg
Study: 20147572
Drug: Levetiracetam 4000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 4000 mg
Study: 20147572
Drug: Diphenhydramine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 400 mg
Study: 20147572
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid 1500 mg
Study: 19931753
Drug: Enzyme-assisted subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-assisted subcutaneous infusion (EASI) with 1-mL injection of 150 U of human recombinant hyaluronidase, followed by 250 mL D5NS infusion.
Study: 19931753
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous (IV) access with 20-gauge IV placement and 250-mL maximal-rate IV bolus of normal saline.
Study: 9059944
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of inactivated hepatitis A vaccine (25 Units) at 0 and 6 months (group A)
Study: 9059944
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of inactivated hepatitis A vaccine (25 Units) at 0, 2, and 6 months (group B)
Study: 3891616
Drug: Tyrosine supplementation
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine supplementation (2.5 g t.i.d.)
Study: 29582077
Drug: intervention patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention patients (free tobacco treatment)
Study: 29582077
Drug: control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: control patients (treatment recommendations)
Study: 20143466
Drug: Preoperative TCF
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1‐14)
Study: 11966889
Drug: Vital pulp
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital pulp therapy with PGE2 measurement
Study: 11805612
Drug: Sygen® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sygen® treatment (specific dosage and duration not mentioned)
Study: 9922519
Drug: Mérieux vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mérieux vaccine, 0.1 ml
Study: 9922519
Drug: Tokio vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tokio vaccine, 0.1 ml
Study: 9922519
Drug: Mérieux vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mérieux vaccine, 0.05 ml
Study: 9922519
Drug: Tokio vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tokio vaccine, 0.05 ml
Study: 7620239
Drug: Salbutamol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (5 mg)
Study: 30135556
Drug: Venlafaxine-XR-plus-mirtazapine combination
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine-XR-plus-mirtazapine combination
Study: 30135556
Drug: Bupropion-plus-escitalopram combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-plus-escitalopram combination
Study: 30135556
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy odds ratio
Study: 30135556
Drug: Venlafaxine-plus-mirtazapine combination
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine-plus-mirtazapine combination odds ratio
Study: 30135556
Drug: Bupropion-plus-escitalopram combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-plus-escitalopram combination odds ratio
Study: 28454823
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) plus oxygen
Study: 18451387
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly intra-articular injections of sodium hyaluronate
Study: 18451387
Drug: Three weekly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weekly intra-articular injections of sodium hyaluronate followed by two weekly intra-articular injections of saline solution